13115 Serum infliximab level in an infant delivered from a mother with psoriatic arthritis receiving infliximab

Abstract

Infliximab (IFX) has been demonstrated to hinder progressive joint destruction induced by PsA. IFX is currently one of the non-contraindicated systemic treatment options during pregnancy. However, little is known about postnatal clearance of infliximab in neonates delivered from psoriasis patients. We measured serum IFX level in an infant delivered from a mother with PsA receiving IFX. A 36-year-old female patient with PsA received 6 mg/kg of IFX every eight weeks. After getting pregnant, she continued it until she was 26 weeks pregnant. She was treated with the same dose of IFX every four weeks from week 18 to 26. She delivered a healthy female baby by caesarean section at week 38 as scheduled. She breastfed her baby. She restarted IFX treatment five weeks after giving birth, and continued IFX treatment every four weeks for one year. Since the patient received IFX treatment during pregnancy and lactation, the serum IFX level in the baby was periodically measured. The concentration of IFX in the serum of the baby was 4.46 μg/mL at 24 days of age; 0.19 μg/mL at 155 days of age; and below the detection level limit at 278 days of age. To the best of our knowledge, there have been no papers reporting the serum IFX levels in a baby delivered from a mother with psoriasis receiving IFX. Further accumulation of case is needed to clarify the safety of IFX in pregnant women with psoriasis and their babies.